BioMarin Pharmaceutical lists 10 executives, led by Alexander Hardy, President, CEO & Director (age 56). Brian R. Mueller CPA is the company's CFO & Executive VP of Finance (age 51).
In fiscal year 2025 the highest-paid executive was Alexander Hardy, President, CEO & Director, with total pay of $3.18 million. The 6 executives with reported pay received $9.66 million in all.
The average age of the executives with a known age is 54; the youngest is 46 and the oldest 63.
Titles, ages and pay from company filings; pay for fiscal year 2025.

President, CEO & Director
CFO & Executive VP of Finance
Executive VP & CTO
Executive VP & Chief Commercial Officer
Executive VP and Chief Research & Development Officer
VP, Chief Accounting Officer & Principal Accounting Officer
Chief Scientific Officer & Senior VP of Research and Early Development
Executive Vice President, Chief Digital & Information Officer
Executive VP, Chief Legal Officer & Secretary
Executive VP & Chief People Officer
| Executive | Title | Age | Total pay |
|---|---|---|---|
| Alexander Hardy | President, CEO & Director | 56 | $3.18 million |
| George Eric Davis J.D. | Executive VP, Chief Legal Officer & Secretary | 54 | $1.31 million |
| Brian R. Mueller CPA | CFO & Executive VP of Finance | 51 | $1.31 million |
| Cristin Hubbard | Executive VP & Chief Commercial Officer | – | $1.29 million |
| Gregory Friberg M.D. | Executive VP and Chief Research & Development Officer | – | $1.28 million |
| C. Greg Guyer Ph.D. | Executive VP & CTO | 63 | $1.27 million |
Total pay as reported for the fiscal year; it can include salary, bonus and stock awards.
Alexander Hardy (President, CEO & Director), age 56; total pay in fiscal year 2025 was $3.18 million.
Brian R. Mueller CPA (CFO & Executive VP of Finance), age 51.
Alexander Hardy, President, CEO & Director, with total pay of $3.18 million in fiscal year 2025.
Alexander Hardy (President, CEO & Director), Brian R. Mueller CPA (CFO & Executive VP of Finance), C. Greg Guyer Ph.D. (Executive VP & CTO), Cristin Hubbard (Executive VP & Chief Commercial Officer) and Gregory Friberg M.D. (Executive VP and Chief Research & Development Officer), and 5 more.